MTOR and neoplasm: Furthermore, although we enhanced the functional rescue experiment using the mTOR agonist MHY1485 and demonstrated that reactivating the PI3K/AKT/mTOR pathway could counteract the tumor suppressive effect of MFAP4, we acknowledged the possibility of off-target effects, which is a common limitation of kinase-targeted compounds.